Health & Food

The highly transmissible Delta variant of SARS-CoV-2 has mutated further to form the ‘Delta plus’ or ‘AY.1’ variant but there is no immediate cause for concern in India as its incidence in the country is still low, scientists said.

Every year on June 8th, World Brain Tumor Day is celebrated. The German Brain Tumor Association initiated this campaign, which is now celebrated globally to raise awareness and educate people about brain tumors. There are many misconceptions and myths concerning brain tumors among the general public, so we'll use this chance to clarify some of them.

United Nations, June 2: The World Health Organisation (WHO) has said only B.1.617.2, one of the three strains of the B.1.617 Covid-19 variant first detected in India, is a “variant of concern” now and noted that lower rates of transmission have been observed for the other two lineages.

The COVID-19 pandemic, continues to impact many people, including cancer patients, their families, and caregivers.Vaccines help a person’s immune system to recognize and protect the body against infections. COVID-19 vaccines have been found to significantly lower the risk of getting infected with COVID-19, lower the risk of having severe disease, being hospitalized, or dying from COVID-19 if one...

May 3: Serum Institute of India Chief Executive Officer Adar Poonawalla has said that India’s Covid-19 vaccine shortage would continue through July, reported The Financial Times. Poonawalla said that the production of the vaccines is expected to increase from 60-70 million doses (6-7 crore) to 100 million (10 crore) by then.

New Delhi, Mar 3: The government has lifted the time restriction on receiving Covid-19 vaccine jabs so as to increase the pace of immunisation, Union Health Minister Harsh Vardhan said on Wednesday.

Geneva, Mar 2: The World Health Organisation (WHO) said that it is "unrealistic" to expect the COVID-19 pandemic to be over by the end of 2021.

As India began new phase of the covid-19 vaccination drive on March 1, registration on the Co-WIN 2.0 portal opened at 9 am. In this phase, people above 60 years and those aged 45 and above with comorbidities will be prioritised.

New Delhi, Feb 27: The NITI Aayog has promulgated a price range of Rs 300-500 for two Covid vaccines that would be available for the priority group at private facilities in the third phase of vaccination set to begin from March 1, sources privy to the development told agencies, adding that the Bharat Biotech's Covaxin would cost a bit higher.

New Delhi, Feb 26: The COVID-19 vaccination sessions will not be held this Saturday and Sunday in view of the Co-Win digital platform transitioning from Co-Win 1.0 to Co-Win 2.0 as India gears up to inoculate people above 60 years and those over 45 years with comorbidities against the infection from March 1.